The DOI matches its Crossref record.
Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin. Cholesterol acyltransferase
Abstract
The human plasma apoproteins apoA-I and apoC-I enhanced the activity of partially purified lecithin: cholesterol acyltransferase five to tenfold with chemically defined phosphatidylcholine:cholesterol single bilayer vesicles as substrates. By contrast, apoproteins apoA-II, apoC-II, and apoC-III did not give any enhancement of enzyme activity. The activation by apoA-I and apoC-I differed, depending upon the nature of the hydrocarbon chains of phosphatidylcholine acyl donor. ApoA-I was most effective with a phosphatidylcholine containing an unsaturated fatty acyl chain. ApoC-I activated LCAT to the same extent with both saturated and unsaturated phosphatidylcholine substrates. Two of the four peptides obtained by cyanogen bromide cleavage of apoA-I retained some ability to activate LCAT. The efficacy of each of these peptides was approximately 25% that of the whole protein. Cyanogen bromide fragments of apoC-I were inactive. The apoproteins from HDL, HDL2, and HDL3, at low protein concentrations, were equally effective as activators of LCATand less effective than apoA-I. Higher concentrations of apoHDL, apoHDL2, and apoHDL3 inhibited LCAT activity. ApoC and apoA-II were both found to inhibit the activation of LCAT by apoA-I. The inhibition of LCAT by higher concentrations of apoHDL was not correlated with the aopA-II and apoC content.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Plasma lipoproteins: apolipoprotein structure and function.
Mahley, R. W., Innerarity, T. L., Rall, S. C., & Weisgraber, K. H. (1984) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34443-6 · Cited by 1,155
Role of apoCs in lipoprotein metabolism: functional differences between apoC1, apoC2, and apoC3
Jong, M. C., Hofker, M. H., & Havekes, L. M. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.3.472 · Cited by 539
Activation of lecithin: cholesterol acyltransferase by human apolipoprotein A-IV.
Steinmetz, A., & Utermann, G. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)89547-3 · Cited by 341
Li, W. H., Tanimura, M., Luo, C. C., Datta, S., & Chan, L. (1988) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38532-1 · Cited by 317
Lipid-protein interactions in the plasma lipoproteins
Morrisett, J. D., Jackson, R. L., & Gotto, A. M. (1977) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/0304-4157(77)90015-6 · Cited by 279
Self-citationBlankenhorn, D. H., Alaupovic, P., Wickham, E., Chin, H. P., & Azen, S. P. (1990) · Circulation · doi:10.1161/01.cir.81.2.470 · Cited by 278
Apolipoproteins in vascular biology and atherosclerotic disease
Mehta, A., & Shapiro, M. D. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00613-5 · Cited by 273
Apolipoprotein C1: Its Pleiotropic Effects in Lipid Metabolism and Beyond
Fuior, E. V., & Gafencu, A. V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235939 · Cited by 186
Structure and evolution of the apolipoprotein multigene family
Luo, C.-C., Li, W.-H., Moore, M. N., & Chan, L. (1986) · Journal of Molecular Biology · doi:10.1016/0022-2836(86)90436-5 · Cited by 173
Human plasma lecithin-cholesterol acyltransferase. An elucidation of the catalytic mechanism.
Jauhiainen, M., & Dolphin, P. J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)62718-3 · Cited by 169
High-density lipoprotein (HDL) metabolism and bone mass
Papachristou, N. I., Blair, H. C., Kypreos, K. E., & Papachristou, D. J. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0657 · Cited by 94
A thumbwheel mechanism for APOA1 activation of LCAT activity in HDL[S]
Cooke, A. L., Morris, J., Melchior, J. T., Street, S. E., Jerome, W. G., Huang, R., Herr, A. B., Smith, L. E., Segrest, J. P., Remaley, A. T., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m085332 · Cited by 92
Self-citationGenetic Mutations Affecting Human Lipoproteins, Their Receptors, and Their Enzymes
Zannis, V. I., Kardassis, D., & Zanni, E. E. (1993) · Advances in Human Genetics 21 · doi:10.1007/978-1-4615-3010-7_3 · Cited by 78
Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer
Zannis, V. I., Chroni, A., Kypreos, K. E., Kan, H.-Y., Cesar, T. B., Zanni, E. E., & Kardassis, D. (2004) · Current Opinion in Lipidology · doi:10.1097/00041433-200404000-00008 · Cited by 74
A consensus model of human apolipoprotein A-I in its monomeric and lipid-free state
Melchior, J. T., Walker, R. G., Cooke, A. L., Morris, J., Castleberry, M., Thompson, T. B., Jones, M. K., Song, H. D., Rye, K.-A., Oda, M. N., et al. (2017) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3501 · Cited by 71
Genetic Mutations Affecting Human Lipoprotein Metabolism
Zannis, V. I., & Breslow, J. L. (1985) · Advances in Human Genetics 14 · doi:10.1007/978-1-4615-9400-0_3 · Cited by 65
Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects
Cohn, J. S., Tremblay, M., Batal, R., Jacques, H., Veilleux, L., Rodriguez, C., Bernier, L., Mamer, O., & Davignon, J. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200055-jlr200 · Cited by 41
Luo, C. C., Li, W. H., & Chan, L. (1989) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38213-4 · Cited by 41
Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans
Cohn, J. S., Batal, R., Tremblay, M., Jacques, H., Veilleux, L., Rodriguez, C., Mamer, O., & Davignon, J. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300209-jlr200 · Cited by 35
“For example, apoC-I has been shown to activate lecithin:cholesterol acyltransferase (LCAT) (11-13), inhibit hepatic lipase (14,15), inhibit phospholipase A2 (16), and also reduce cholesterol ester transfer protein activity (17,18).”
BackgroundRajaram, O. V., & Barter, P. J. (1985) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(85)90028-1 · Cited by 31
Apolipoprotein A1 Forms 5/5 and 5/4 Antiparallel Dimers in Human High-density Lipoprotein
He, Y., Song, H. D., Anantharamaiah, G. M., Palgunachari, M. N., Bornfeldt, K. E., Segrest, J. P., & Heinecke, J. W. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.000878 · Cited by 29
Metabolism of apolipoprotein C–I in normolipoproteinemic human subjects
MALMENDIER, C., LONTIE, J., GRUTMAN, G., & DELCROIX, C. (1986) · Atherosclerosis · doi:10.1016/0021-9150(86)90063-8 · Cited by 27
Apolipoprotein CI Knock-Out Mice Display Impaired Memory Functions
Berbée, J. F. P., Vanmierlo, T., Abildayeva, K., Blokland, A., Jansen, P. J., Lütjohann, D., Gautier, T., Sijbrands, E., Prickaerts, J., Hadfoune, M., et al. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100576 · Cited by 25
Annuzzi, G., Holmquist, L., & Carlson, L. A. (1989) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365518909089080 · Cited by 25
Metadata
- Authors
- Soutar, A. K., Garner, C. W., Baker, H. N., Sparrow, J. T., Jackson, R. L., Gotto, A. M., & Smith, L. C.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1975-07
- Volume
- 14
- Issue
- 14
- Pages
- 3057-3064
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2001697469
- Cited by
- 392
- References
- 0
- FWCI
- 31.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.